Loading...
•
Jun 30, 2022
Essa Pharma Q3 2022 Earnings Report
Provided a corporate update and reported financial results for the fiscal third quarter ended June 30, 2022.
Key Takeaways
ESSA Pharma reported their Q3 financial results, highlighting the advancement of their lead candidate, EPI-7386, into the dose expansion phase and the initiation of combination trials. The company's cash position is expected to be sufficient to fund operations through 2024.
EPI-7386 is advancing into the dose expansion phase of the single agent trial.
The second cohort of patients was dosed in the company-sponsored combination trial with enzalutamide.
Additional trials of EPI-7386 are planned for initiation in earlier-line patients.
Clinical results from the Phase 1a dose escalation study demonstrated that EPI-7386 was safe and well-tolerated.
Essa Pharma
Essa Pharma
Forward Guidance
ESSA Pharma's cash position is expected to be sufficient to fund current and planned operations through 2024.